SEC Filing Summary: Nile Therapeutics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Nile Therapeutics, Inc. on January 28, 2008, covering events occurring on January 25, 2008. The registrant is a Delaware corporation headquartered in Berkeley, California. Note: The request metadata references "Capricor Therapeutics, Inc.," but the filing text explicitly identifies the registrant as "Nile Therapeutics, Inc."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the appointment of Gregory W. Schafer to the Board of Directors and as Chairperson of the Audit Committee, effective January 25, 2008.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, risk factors, contingencies, or unusual items. It references a press release (Exhibit 99.1) regarding the appointment but does not include its full text within the provided content.
Key Facts for Investor Verification
- Gregory W. Schafer was appointed to the Board of Directors and Audit Committee Chair on January 25, 2008.
- The filing is a governance update (Item 5.02) and contains no financial performance data.
- Investors should verify the background and qualifications of the newly appointed director, Gregory W. Schafer.
- Investors should review the attached press release (Exhibit 99.1) for additional context on the appointment.